Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 12
Submit an article Journal homepage
4,862
Views
101
CrossRef citations to date
0
Altmetric
Special Report

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

Shibo Jiang Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA; Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China; Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA; Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China
,
Maria Elena Bottazzi Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA
,
Lanying Du Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA
,
Sara Lustigman Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA
,
Chien-Te Kent Tseng Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA
,
Elena Curti Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA
,
Kathryn Jones Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA
,
Bin Zhan Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA
&
Peter J Hotez Sabin Vaccine Institute, Washington, DC, USA; Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA; Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Departments of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute, Washington, DC, USA. [email protected]
 show all
Pages 1405-1413 | Published online: 09 Jan 2014

References

  • Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS‑CoV – a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7(3), 226–236 (2009).
  • Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev. Vaccines 8(7), 887–898 (2009).
  • Jaume M, Yip MS, Kam YW et al. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med. J. 18(Suppl. 2), 31–36 (2012).
  • Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279(5), 3197–3201 (2004).
  • Du L, Zhao G, Li L et al. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem. Biophys. Res. Commun. 384(4), 486–490 (2009).
  • Du L, Zhao G, Chan CC et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 393(1), 144–150 (2009).
  • Li W, Moore MJ, Vasilieva N et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965), 450–454 (2003).
  • He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174(8), 4908–4915 (2005).
  • He Y, Zhu Q, Liu S et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334(1), 74–82 (2005).
  • He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol. 176(10), 6085–6092 (2006).
  • Du L, Zhao G, He Y et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25(15), 2832–2838 (2007).
  • Cao Z, Liu L, Du L et al. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol. J. 7, 299 (2010).
  • Chen Z, Zhang L, Qin C et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79(5), 2678–2688 (2005).
  • Du L, Zhao G, Chan CC et al. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 23(2), 211–219 (2010).
  • Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53, 303–321 (2010).
  • Baldwin SL, Shaverdian N, Goto Y et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27(43), 5956–5963 (2009).
  • Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23–32 (2009).
  • Behzad H, Huckriede AL, Haynes L et al. GLA-SE, a synthetic Toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205(3), 466–473 (2012).
  • Olsen CW. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet. Microbiol. 36(1–2), 1–37 (1993).
  • Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp. Immunol. Microbiol. Infect. Dis. 4(2), 175–189 (1981).
  • Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 5(12), 917–927 (2005).
  • Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 39(1-3), 225–239 (2007).
  • Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 82(5), 2040–2055 (2008).
  • Bolles M, Deming D, Long K et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).
  • Deming D, Sheahan T, Heise M et al. Vaccine efficacy in senescent mice challenged with recombinant severe acute respiratory syndrome-coronavirus bearing epidemic and zoonotic spike variants. PLoS Med. 3(12), e525 (2006).
  • Yasui F, Kai C, Kitabatake M et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181(9), 6337–6348 (2008).
  • Delgado MF, Coviello S, Monsalvo AC et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15(1), 34–41 (2009).
  • Tseng CT, Sbrana E, Iwata-Yoshikawa N et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7(4), e35421 (2012).
  • Jaume M, Yip MS, Kam YW et al. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med. J. 18(Suppl. 2), 31–36 (2012).
  • Hotez P. A handful of ‘antipoverty’ vaccines exist for neglected diseases, but the world’s poorest billion people need more. Health Aff. (Millwood) 30(6), 1080–1087 (2011).
  • Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J. Pharm. Sci. doi:10.1002/jps.22618 (2011) (Epub ahead of print).
  • Plieskatt JL, Rezende WC, Olsen CM et al. Advances in vaccines against neglected tropical diseases: enhancing physical stability of a recombinant hookworm vaccine through biophysical and formulation studies. Hum. Vaccin. Immunother. 8(6), 765–776 (2012).
  • Tseng CT, Huang C, Newman P et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J. Virol. 81(3), 1162–1173 (2007).
  • McCray PB Jr, Pewe L, Wohlford-Lenane C et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813–821 (2007).
  • Goud GN, Bottazzi ME, Zhan B et al. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine 23(39), 4754–4764 (2005).
  • Asojo OA, Goud G, Dhar K et al. X-ray structure of Na-ASP-2, a pathogenesis-related-1 protein from the nematode parasite, Necator americanus, and a vaccine antigen for human hookworm infection. J. Mol. Biol. 346(3), 801–814 (2005).
  • Asojo OA, Homma K, Sedlacek M et al. X-ray structures of Na-GST-1 and Na-GST-2 two glutathione S-transferase from the human hookworm Necator americanus. BMC Struct. Biol. 7, 42 (2007).
  • Goud GN, Deumic V, Gupta R et al. Expression, purification, and molecular analysis of the Necator americanus glutathione S-transferase 1 (Na-GST-1): a production process developed for a lead candidate recombinant hookworm vaccine antigen. Protein Expr. Purif. 83(2), 145–151 (2012).
  • Bethony JM, Simon G, Diemert DJ et al. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine 26(19), 2408–2417 (2008).
  • Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat. Rev. Microbiol. 8(11), 814–826 (2010).
  • Burns DL. Licensure of vaccines using the Animal Rule. Curr. Opin. Virol. 2(3), 353–356 (2012).
  • Roberts A, Deming D, Paddock CD et al. A mouse-adapted SARS-coronavirus causes disease and mortality in Balb/c mice. PLoS Pathogens 3, e5 (2007).
  • Hearty S, Conroy PJ, Ayyar BV, Byrne B, O’Kennedy R. Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Expert Rev. Vaccines 9(6), 645–664 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.